$25.72
-0.02-0.08%
At close: -
$25.75
0.030.12%
After Hours: 7:38 PM EDT
Comments
Loading...
Catalyst Pharmaceuticals Stock Guidance | NASDAQ:CPRX | Benzinga
Catalyst Pharmaceuticals issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/26/2025 | CPRX | Catalyst Pharmaceuticals | FY | 2025 | — | — | — | $545.00M | $565.00M | $558.08M | Get Alert |
| 11/06/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $475.00M | $485.00M | $473.67M | Get Alert |
| 08/07/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $455.00M | $475.00M | $462.43M | Get Alert |
| 05/08/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $455.00M | $475.00M | $460.53M | Get Alert |
| 02/28/2024 | CPRX | Catalyst Pharmaceuticals | FY | 2024 | — | — | — | $455.00M | $475.00M | $463.19M | Get Alert |
| 11/08/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $390.00M | $395.00M | $389.14M | Get Alert |
| 08/09/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $380.00M | $390.00M | $380.21M | Get Alert |
| 06/01/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $380.85M | Get Alert |
| 05/10/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $381.54M | Get Alert |
| 03/15/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $380.33M | Get Alert |
| 02/07/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $214.00M | $214.00M | $210.36M | Get Alert |
| 02/07/2023 | CPRX | Catalyst Pharmaceuticals | FY | 2023 | — | — | — | $375.00M | $385.00M | $337.63M | Get Alert |
| 02/07/2023 | CPRX | Catalyst Pharmaceuticals | Q4 | 2022 | — | — | — | $61.00M | $61.00M | $56.84M | Get Alert |
| 11/09/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $205.00M | $210.00M | $205.03M | Get Alert |
| 08/09/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $200.85M | Get Alert |
| 05/10/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $199.99M | Get Alert |
| 03/16/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $198.45M | Get Alert |
| 02/07/2022 | CPRX | Catalyst Pharmaceuticals | Q4 | 2021 | — | — | — | $38.00M | $38.00M | $36.85M | Get Alert |
| 02/07/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2021 | — | — | — | $141.00M | $141.00M | $138.30M | Get Alert |
| 02/07/2022 | CPRX | Catalyst Pharmaceuticals | FY | 2022 | — | — | — | $195.00M | $205.00M | $163.53M | Get Alert |
FAQ
What is the most recent guidance for Catalyst Pharmaceuticals (CPRX)?
There have been no specific sales or earnings guidance reported for Catalyst Pharmaceuticals in recent months.
Browse guidance and forecast on all stocks.